Arcoma AB (ARCOMA.ST)
SEK 10.95
(3.3%)
SEK 10.95
(3.3%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 81.96 Million SEK | -18.31% |
| 2022 | 100.33 Million SEK | 26.57% |
| 2021 | 79.26 Million SEK | -16.59% |
| 2020 | 95.03 Million SEK | 14.04% |
| 2019 | 83.33 Million SEK | 9.25% |
| 2018 | 76.27 Million SEK | 11.98% |
| 2017 | 68.11 Million SEK | -4.41% |
| 2016 | 71.25 Million SEK | -15.43% |
| 2015 | 84.25 Million SEK | 6.37% |
| 2014 | 79.21 Million SEK | 11.77% |
| 2013 | 70.87 Million SEK | 3.47% |
| 2012 | 68.49 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 87.28 Million SEK | 4.24% |
| 2024 Q1 | 95.51 Million SEK | 16.54% |
| 2024 Q2 | 83.73 Million SEK | -12.34% |
| 2023 Q3 | 95.81 Million SEK | 7.14% |
| 2023 FY | 81.96 Million SEK | -18.31% |
| 2023 Q2 | 89.43 Million SEK | -4.9% |
| 2023 Q1 | 94.04 Million SEK | -6.27% |
| 2023 Q4 | 81.96 Million SEK | -14.46% |
| 2022 Q4 | 100.33 Million SEK | 8.46% |
| 2022 Q3 | 92.5 Million SEK | 5.76% |
| 2022 FY | 100.33 Million SEK | 26.57% |
| 2022 Q1 | 82.11 Million SEK | 3.58% |
| 2022 Q2 | 87.46 Million SEK | 6.53% |
| 2021 Q4 | 79.26 Million SEK | -12.46% |
| 2021 Q1 | 95.75 Million SEK | 0.76% |
| 2021 Q2 | 97.68 Million SEK | 2.01% |
| 2021 Q3 | 90.55 Million SEK | -7.3% |
| 2021 FY | 79.26 Million SEK | -16.59% |
| 2020 FY | 95.03 Million SEK | 14.04% |
| 2020 Q4 | 95.03 Million SEK | 2.2% |
| 2020 Q3 | 92.98 Million SEK | 8.53% |
| 2020 Q1 | 96.17 Million SEK | 15.41% |
| 2020 Q2 | 85.67 Million SEK | -10.92% |
| 2019 Q4 | 83.33 Million SEK | -0.86% |
| 2019 Q1 | 73.75 Million SEK | -3.3% |
| 2019 FY | 83.33 Million SEK | 9.25% |
| 2019 Q3 | 84.04 Million SEK | 0.84% |
| 2019 Q2 | 83.35 Million SEK | 13.01% |
| 2018 Q2 | 73.48 Million SEK | -1.78% |
| 2018 Q3 | 78.72 Million SEK | 7.13% |
| 2018 Q4 | 76.27 Million SEK | -3.12% |
| 2018 FY | 76.27 Million SEK | 11.98% |
| 2018 Q1 | 74.81 Million SEK | 9.84% |
| 2017 Q4 | 68.11 Million SEK | -0.1% |
| 2017 FY | 68.11 Million SEK | -4.41% |
| 2017 Q3 | 68.18 Million SEK | -7.62% |
| 2017 Q2 | 73.8 Million SEK | 3.1% |
| 2017 Q1 | 71.58 Million SEK | 0.47% |
| 2016 Q2 | 76.44 Million SEK | 0.33% |
| 2016 Q4 | 71.25 Million SEK | -9.71% |
| 2016 FY | 71.25 Million SEK | -15.43% |
| 2016 Q1 | 76.19 Million SEK | -9.57% |
| 2016 Q3 | 78.91 Million SEK | 3.23% |
| 2015 Q1 | 83.32 Million SEK | 5.19% |
| 2015 FY | 84.25 Million SEK | 6.37% |
| 2015 Q4 | 84.25 Million SEK | -1.02% |
| 2015 Q3 | 85.12 Million SEK | 15.13% |
| 2015 Q2 | 73.93 Million SEK | -11.27% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 Q3 | 84.19 Million SEK | 0.0% |
| 2014 Q4 | 79.21 Million SEK | -5.92% |
| 2014 FY | 79.21 Million SEK | 11.77% |
| 2013 Q4 | 70.87 Million SEK | 0.0% |
| 2013 FY | 70.87 Million SEK | 3.47% |
| 2012 FY | 68.49 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Acarix AB (publ) | 62.88 Million SEK | -30.338% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 97.507% |
| ADDvise Group AB (publ) | 3.28 Billion SEK | 97.507% |
| Bactiguard Holding AB (publ) | 682.87 Million SEK | 87.998% |
| BICO Group AB (publ) | 10.19 Billion SEK | 99.196% |
| Boule Diagnostics AB (publ) | 755.1 Million SEK | 89.146% |
| CellaVision AB (publ) | 928.71 Million SEK | 91.175% |
| Clinical Laserthermia Systems AB (publ) | 57.72 Million SEK | -41.987% |
| Chordate Medical Holding AB (publ) | 21.95 Million SEK | -273.31% |
| C-Rad AB (publ) | 404 Million SEK | 79.712% |
| Duearity AB (publ) | 15.14 Million SEK | -441.218% |
| Dignitana AB (publ) | 44.83 Million SEK | -82.824% |
| Episurf Medical AB (publ) | 104.3 Million SEK | 21.417% |
| Getinge AB (publ) | 55.09 Billion SEK | 99.851% |
| Scandinavian Real Heart AB (Publ) | 102.63 Million SEK | 20.145% |
| Iconovo AB (publ) | 128.07 Million SEK | 36.007% |
| Integrum AB (publ) | 164.85 Million SEK | 50.284% |
| Luxbright AB (publ) | 40.68 Million SEK | -101.447% |
| Mentice AB (publ) | 322.52 Million SEK | 74.587% |
| OssDsign AB (publ) | 356.38 Million SEK | 77.002% |
| Paxman AB (publ) | 167.12 Million SEK | 50.958% |
| Promimic AB (publ) | 92.87 Million SEK | 11.75% |
| Qlife Holding AB (publ) | 39.04 Million SEK | -109.911% |
| SciBase Holding AB (publ) | 64.33 Million SEK | -27.401% |
| ScandiDos AB (publ) | 81.47 Million SEK | -0.6% |
| Sectra AB (publ) | 3.21 Billion SEK | 97.447% |
| Sedana Medical AB (publ) | 1.01 Billion SEK | 91.917% |
| Senzime AB (publ) | 433.54 Million SEK | 81.095% |
| SpectraCure AB (publ) | 144.83 Million SEK | 43.41% |
| Stille AB | 804.89 Million SEK | 89.817% |
| Vitrolife AB (publ) | 16.39 Billion SEK | 99.5% |
| Xvivo Perfusion AB (publ) | 2.19 Billion SEK | 96.267% |